BUZZ-Pacira rises on deal to sell pain relief device business

Zimmer Biomet Holdings, Inc.
Pacira Biosciences, Inc.

Zimmer Biomet Holdings, Inc.

ZBH

0.00

Pacira Biosciences, Inc.

PCRX

0.00

** Shares of Pacira BioSciences PCRX.O rise 3.8% to $26.05 premarket

** The drugmaker to sell its iovera business to medical device maker Zimmer Biomet ZBH.N for up to $140 million, including $70 million upfront and up to $70 million in milestone payments through 2031

** Iovera is a drug-free device that uses cold therapy to temporarily block nerve pain, including pain tied to knee osteoarthritis and knee-replacement surgery

** PCRX says ZBH will get all rights to develop, manufacture and sell iovera

** The companies will also work together on a program for spasticity, or muscle stiffness and spasms

** The deal is expected to close in Q3 2026, subject to customary conditions

** As of last close, PCRX down 3.1% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.